Northrop Grumman heads into Wednesday's Q2 earnings with options traders more cautious than at any point in months, even as the short-selling community remains largely on the sidelines.
The options signal is the sharpest data point in the setup. The put/call ratio has climbed to 1.05, more than two standard deviations above its 20-day average of 0.98 — the highest defensive skew of the past year outside one prior spike. That shift has arrived alongside a meaningful price decline: the stock closed Tuesday at $512.29, down 2.2% on the day and 3.1% on the week, extending a slide that has now erased roughly 1.8% over the past month. The combination of falling price and rising put demand points to genuine hedging pressure into the print, not routine positioning.
Short interest tells a much less dramatic story. At 1.6% of the free float, bearish conviction through the borrow market is minimal. Borrow availability is effectively unlimited — the lending pool is so deep relative to demand that availability reads at the ceiling of the scale. Cost to borrow has roughly doubled over the past week to 0.78%, which sounds striking, but the absolute level remains negligible for a stock of this size. There is no squeeze risk, no crowded short. The defensive tone is in options, not in the short book.
The analyst debate has tilted visibly negative in recent weeks, though not catastrophically so. Every firm that has acted since mid-June — Goldman Sachs, TD Cowen, Citigroup, Jefferies — has cut its price target while holding onto a positive or neutral rating. Goldman's revised target of $533 now sits barely above the current price, a sharp compression from its prior $603. The consensus mean of roughly $655 implies around 28% upside, but that number has been built by targets chasing the stock lower rather than fresh conviction. The bull case rests on long-duration programs — B-21 production ramp, F/A-XX, and the emerging Golden Dome opportunity — that generate durable revenue well into the decade. Bears focus on nearer-term pain: space segment softness from program realignments and lost contracts, and management's shift toward reinvestment over buybacks, which raises questions about near-term cash return. Peers offer limited comfort: fell 2.1% on the week, dropped 2.8%, and shed more than 5%, suggesting sector-wide pressure rather than NOC-specific weakness.
One institutional data point is worth noting. Capital Research and Management added roughly 1.07 million shares in the quarter to June, lifting its stake to nearly 11% of shares outstanding — the largest holder by some distance. T. Rowe Price also added 700,000 shares in the same period. Those are meaningful votes of confidence, though they predate the most recent leg of the selloff.
Wednesday's print is ultimately a test of whether the space segment is genuinely stabilising and whether management can offer a credible path back toward the revenue growth trajectory that justified the stock's prior premium — two questions that options traders are clearly not taking for granted.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
